| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| age/gender | 53/F | 61/F | 58/M | 27/M | 65/M | 58/F | 36/F | 47/F | 32/F | 35/F | 63/F | 61/F |
| Fever | (−) | (+) | (−) | (−) | (−) | (−) | (−) | (+) | (+) | (−) | (−) | (−) |
| Skin manifestation | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) |
| Arthritis/arthralgia | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (−) | (−) | (+) | (−) |
| Muscle weakness | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | (−) | (−) |
| Raynaud’s phenomenon | (+) | (+) | (+) | (−) | (−) | (+) | (−) | (+) | (−) | (−) | (−) | (+) |
| Sclerodactyly | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (+) | (−) | (−) | (−) | (−) |
| Sicca syndrome | (−) | (+) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | (−) | (+) | (−) |
| ANA | (+) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | (−) | (−) | (−) | (−) |
| RF | (−) | (+) | (+) | (−) | (−) | (−) | (+) | (−) | (−) | (−) | (+) | (−) |
| Anti-ARS | EJ | PL−12 | EJ | OJ | KS | KS | KS | PL−12 | OJ | PL−12 | EJ | KS |
| Other antibodies | (−) | SSA | (−) | (−) | (−) | (−) | (−) | (−) | (−) | SSA | (−) | (−) |
| %VC (%) | 78 | 65 | 78 | 74 | 67 | 85 | 35 | 56 | 36 | 74 | 86 | n.d. |
| DLco/VA ml/min/Torr/l) | 5.2 | 5.0 | 3.0 | 5.9 | 4.3 | 4.2 | n.a. | 4.5 | 4.1 | 4.2 | 4.9 | n.a. |
| KL-6 (U/ml) | 231 | 1620 | 957 | 1410 | 1470 | 1520 | n.a. | 742 | 1700 | 7080 | 2040 | 1230 |
| Pathological findings | OP | NSIP | DIP | UIP | n.a. | LIP | n.d. | UIP | NSIP | n.a. | NSIP | n.d. |
| Uptake in Gallium scintigram | (+) | (+) | (+) | (+) | (+) | (−) | (+) | (−) | n.d. | n.d. | n.d. | n.d. |
| PSL (mg/day) | (−) | 40 | 60 | 60 | 40 | (−) | (−) | (−) | 50 | Pulse/70 | 60 | (−) |
| Immunosuppressant | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (−) | (+) | (−) | (−) |
| Outcome | nca | slpb | nc | impc | slp | nc | slp | nc | imp | imp | imp | nc |